Explore the latest developments showcased at World ADC, highlighting smarter payloads and precise targeting in drug discovery.

Dr. Hope Rugo explains how antibody-drug conjugates like Datroway and Trodelvy are shifting the treatment landscape for ...

Barclays sees the company's antibody-drug conjugate data in 2026 as a potential source of upside. ・MacroGenics CEO Eric Risser said on Monday that the company anticipates several important milestones ...

The market for Antibody-drug Conjugates (ADCs) in oncology presents significant opportunities with over 200 companies and 220 drugs in development globally. ADCs offer high specificity and reduced ...

Explore the World ADC Conference highlights on antibody-drug conjugates and their impact on cancer therapy and clinical ...

Kyowa Kirin has decided to discontinue all clinical development of its OX40 drug after two new cancer cases emerged. | Kyowa Kirin has decided to discontinue all clinical development of its OX40 drug ...

Antibody-drug conjugates (ADCs) are typically composed of a monoclonal antibody attached to a cytotoxic drug via a chemical linker. The antibody is able to identify biomarkers on and attach to cancer ...

Oncology is one of Ipsen’s three core therapeutic areas, and the company has been actively striking deals that add cancer drugs to its portfolio and pipeline. The latest deal brings its first antibody ...

A Chinese phase 3 trial of Bristol Myers Squibb’s antibody-drug conjugate has hit its dual primary survival endpoints, ...

The concept of an antibody drug conjugate, or ADC, is straightforward: a cancer-killing drug is chemically linked to an antibody that targets the delivery of the therapy to a tumor. This drug class ...